Greenscape Land Design Inc. company information, Employees & Contact Information

Consumer confidence dips as markets rally The Real Economy Blog

When David Surrenders the Sling: The Misalignment of Science and Strategy in Biotech-Pharma Partnerships Cureus

FM appoints Liberty Mutual’s Erbig as new CFO Insurance Insider US

Nobuhiro Hosoki Cinema Daily US

EY US - Home | Building a better working world EY

Driving change: The new roadmap for automotive retail transformation RSM

Overlap of Toxic Epidermal Necrolysis (TEN)-Like Cutaneous Lupus and Rowell Syndrome in Systemic Lupus Erythematosus: A Case-Based Review Cureus

Higher cedant retention on property cat a headwind for reinsurance: Arch CEO Insurance Insider US

Massive Nationwide Cancer Charity Fraud Scheme Serves as Warning Oncology News Central

AstraZeneca Foundation awards over $1.4M in third year grants to advance healthcare access; announces 2026 call for applications AstraZeneca US

Recent Trends in the Pharmacological Treatment of Chronic Migraine: A Systematic Review of Randomized Controlled Trials Cureus

Holly Starks Acquires the Flumberico Brand, Expanding the Vision Behind flumberico.us.com Yahoo Finance

‘No further re-underwriting of the casualty book’ needed: Everest CFO Insurance Insider US

Market Minute: Falling bond yields and economic imbalances The Real Economy Blog

AdvaMed Code of Ethics® AdvaMed® - Advanced Medical Technology Association®

BofA Launches ‘Golf with Us’ to Bring Affordable Rounds to More Than 50,000 Youth Nationwide Bank of America

Comparative Outcomes of Hilar Control in Laparoscopic Partial Nephrectomy: Satinsky Clamp Versus Bulldog Clamp Cureus

The Hartford pulling back in large property over pricing concerns Insurance Insider US

FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery AstraZeneca US

Exosomes as Central Mediators of Host-Pathogen Interactions in Periodontitis: A Systematic Literature Review Cureus

Car donation charity fined millions, accepts fundraising restrictions in Colorado and 18 other states CBS News

U.S.A. Home Hitachi Global

Scam charity claiming to donate money to breast cancer support shut down WECT

Empowering Action in Asthma Care This Season and Beyond AstraZeneca US

iPR Pharmaceuticals Earns its 1st EPA’s ENERGY STAR® Certification for Superior Energy Efficiency AstraZeneca US

AstraZeneca impact in the US AstraZeneca US

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer AstraZeneca US

Our impact, our people AstraZeneca US

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D AstraZeneca US

Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial AstraZeneca US

Celebrating National Nonprofit Day: Partnerships That Transform Healthcare Access AstraZeneca US

AIRSUPRA ® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol AstraZeneca US

Kars-R-Us scam using breast cancer support shut down The Center Square

Delaware AG joins lawsuit against 'deceptive' breast cancer fundraising operation Delawareonline.com

TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer AstraZeneca US

CONSUMER PROTECTION NEWS: FTC, 19... VitalLaw.com

Nationwide Fake Cancer Charity Scam Busted, Kars-R-Us.com Inc. Accused Hoodline

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma AstraZeneca US

Partnerships in Motion: How Cross-Sector Collaboration is Powering Broader Clinical Trial Representation AstraZeneca US

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial AstraZeneca US

Trump calls for using US cities as a ‘training ground’ for military in unusual speech to generals Federal News Network

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial AstraZeneca US

Cambrian Works Selects Astroscale U.S. as its Mission Partner for NASA Swift Observatory Boost Mission Concept Study SpaceNews

Be careful with online Joann closure sales Canton Repository

Luv n' care Recalls Nuby Stroller Fans Due to Laceration Injury Hazard U.S. Consumer Product Safety Commission (.gov)

American Rheinmetall secures order for T-158 tracks Rheinmetall

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial AstraZeneca US

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer AstraZeneca US

Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide" PR Newswire

Announcing the 2024 Power of Us Award winners AstraZeneca US

Do Not Shop On Any Website That’s On This List Forbes

Leonardo US Cyber and Security Solutions, LLC Announces MC_linX Platform/MOSAIC Will Power Nokia’s Next-Generation Mission-Critical Communications Business Wire

US Com Sec Lutnick says again on tariffs that 10 is baseline, no one’s going below 10 investingLive

TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial AstraZeneca US

Rheinmetall completes acquisition of Loc Performance in the USA Rheinmetall

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer AstraZeneca US

Announcing the 2024-2025 US ACT on Health Equity Community Investments Recipients AstraZeneca US

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca US

Collective Action to Advance Health Equity AstraZeneca US

FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis AstraZeneca US

What science can do AstraZeneca US

Affordability AstraZeneca US

AIRSUPRA (PT027) approved in the US for asthma AstraZeneca US

Announcing the 2023 Power of Us Award winners AstraZeneca US

Scot Anderson Womble Bond Dickinson

The Real Economy: October 2025 RSM

TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer AstraZeneca US

US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) AstraZeneca US

Tracy A. Bacigalupo Womble Bond Dickinson

Leadership RSM

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in US for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens AstraZeneca US

Join RSM's global workforce in El Salvador RSM

Investigator Sponsored Studies (ISS) Program Novo Nordisk U.S. Website

TEZSPIRE approved for self-administration in the US with a new pre-filled pen AstraZeneca US

Rewards and benefits RSM

AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial AstraZeneca US

FluMist approved for self-administration in the US AstraZeneca US

Who We Are Otsuka US

Careers AstraZeneca US

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial AstraZeneca US

WAINUA (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis AstraZeneca US

Nonprofit and education RSM

ispace-US and Rhea Space Activity Sign Payload Services Agreement Aimed at Expanding Deep Space Technological Capabilities ispace

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH AstraZeneca US

Contact Us AstraZeneca US

ispace - U.S. Announces new U.S. Headquarters, Unveils APEX 1.0 Lunar Lander, Provides Updates on Mission 3 ispace

TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer AstraZeneca US

Product patents Novo Nordisk U.S. Website

Alexander P. Wharton Womble Bond Dickinson

Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer AstraZeneca US

IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US AstraZeneca US

FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients AstraZeneca US

IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer AstraZeneca US

Portraits of Lung Cancer AstraZeneca US

ispace-U.S. Accelerates its Mission 3 Utilizing Agile Development with Fusion by Stoke Space ispace

Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial AstraZeneca US

Agreement to takeover US vehicle specialist Loc Performance Rheinmetall

SAPHNELO (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus AstraZeneca US

BYDUREON BCise (exenatide extended-release) approved in the US for the treatment of type 2 diabetes in pediatric patients ages 10 years and older AstraZeneca US

Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma AstraZeneca US